Ozempic 0,25 mg and 0,5 mg Solution for injection (injection).
PDF Leaflet Revision Date: 17 February 2023
Clinical Summary
Quick overview from the medicine insert
Indication
For treatment of adults with insufficiently controlled type 2 diabetes mellitus.
Dosage (summary)
Starting dose: 0.25 mg once weekly, increase to 0.5 mg after 4 weeks, then to 1 mg if needed.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; effective contraception advised.
Key Drug Interactions
- Sulfonylureas
- Insulin
Contraindications
- Hypersensitivity to semaglutide
- Personal/family history of MTC
- MEN 2
Common side effects
- Nausea
- Diarrhoea
- Vomiting
- Hypoglycaemia
Counselling Points
- Monitor for symptoms of thyroid tumours
- Avoid hypoglycaemia when driving
- Do not mix with other medications
Serious warnings
- Risk of thyroid C-cell tumours
- Acute pancreatitis
- Diabetic retinopathy complications
Important Disclaimer
The Ozempic 0,25 mg and 0,5 mg Solution for injection (injection). professional information leaflet below is the property of Novo Nordisk and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
